Postdoctoral - Virology, University of California, Los Angeles
Postdoctoral - Cell Biology, University of New Mexico
PhD - Immunology, University of Manitoba
BSc - Microbiology, University of Manitoba
PH 236: U.S. Food and Drug Administration, Drug Development, Public Health, and Health Policy
Veronica Miller is a leading expert in the process of engaging stakeholders from both sides of the Atlantic to resolve significant health policy and public health issues. She has extensive experience in working with major global and U.S. organizations and agencies involved in HIV research and policy. Efforts led by Miller to advance public health policy through stakeholder engagement include the National Summit program, which focuses on the implementation of the National HIV/AIDS Strategy and the Viral Hepatitis Action Plan; and the Bay Area Health Disparities Program.
As a Professor (Adjunct), Miller teaches a graduate-level course she developed on FDA and drug development, based on case studies from the Forum’s rich history in facilitating drug development. She mentors interns and fellows pursuing regulatory, biotech, and translational medicine careers.
She joined the Forum for Collaborative Research in 2001 after having directed the interdisciplinary HIV Research Group at the HIV Outpatient Clinic of the JW Goethe University in Frankfurt, Germany. Together with Joep Lange, she co-founded and chaired the Euro-Guidelines Group on HIV Drug Resistance, the first pan-European group established for the purpose of assuring a common standard-of-care for patients in all European states.
Miller served on numerous industry and government advisory boards throughout her career, publishing over 90 peer-reviewed publications on HIV treatment strategies and regulatory strategies for HIV and HCV.
- Advancing regulatory science for unmet medical/public health needs
- Collaborative frameworks for drug development
- Translating biomedical innovation to global access
- Disease areas: HIV, HCV, HBV, CMV, liver diseases
In 2001, Miller joined the Forum for Collaborative Research—a public/private partnership addressing cutting-edge science and policy issues through a process of stakeholder engagement and deliberation—as executive director. The Forum brings together researchers and advocates, national and international regulatory agencies, pharmaceutical and diagnostic companies, health care providers, and private foundations to compare data and debate consequences. The Forum also identifies gaps and impediments, frames issues, and helps set research strategy.
Under her leadership, the Forum for Collaborative Research extended its deliberative process to advance regulatory science (applied successfully to HIV) to drug development for hepatitis C infection, the treatment of liver diseases (NASH and fibrosis), and human cytomegalovirus disease in solid organ and stem cell transplant patients.
Prior to 2001, Miller’s own research focused on randomized clinical trials and observational cohorts to determine factors associated with HIV treatment outcomes, including the impact of drug resistance, documented in more than 50 peer-reviewed articles. Her original research work contributed to FDA and EMA guidelines on assessment and reporting of drug resistance and the generation of international guidelines for drug resistance testing.
- HIV Cure Project
- Overcoming Health Disparities in the Bay Area Using HIV/AIDS and HCV as Models
- HCV Drug Development Advisory Group
- Facilitating Drug Development for the Treatment of Liver Disease
- Facilitating Drug Development for the Prevention and Treatment of CMV Disease in Transplantation Settings
- Pre-Exposure Prophylaxis and Microbicide Research
- HBV Therapeutic and Curative Interventions
- Pediatric HIV Clinical Trials
- Addressing the Regulatory Challenges of Primary Sclerosing Cholangitis (PSC) to Advance Therapeutic Interventions
Natori Y, Algahamdi A, Tazari Mahmood, Miller V, Husain S, Komatsu T, Griffiths P, Ljungman P, Orchanian-Cheff A, Kumar D, Humar A. Can Viral Load be used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis. CMV. CID 2017. In press. DOI 10.1093/cid/cix793
Patel YA, Imperial JC, Muir A, Quentin M, Debrota DJ, Dimick-Santos L, Filozof C, Metha R, Sanyal AS, Schabel E, Neuschwander-Tetri BA, Miller V. Baseline parameters in clinical trials for nonalcoholic steatohepatitis: Recommendations from the Liver Forum. Gastroenterology 2017; In press. DOI 10.1053/j.gastro.2017.07.024
Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe AYM, Miller V, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore DJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky J-M, Feld JJ, Schinkel J, Garcia F, Lennerstarnd J, Applegate TL. Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. Hepatology Communications 2017; in press. DOI 10.1002/hep4.1050
Liu J, Goicochea P, Block T, Brosgart CL, Donaldson EF, Lenz O, Lim SG, Marins EG, Mishra P, Peters MG, Miller V. Advancing the regulatory path on hepatitis B virus treatment and curative research: A stakeholders' consultation. Journal of Virus Eradication 2017; 3:1-6.
Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. CID 2017; 64(1):87-91. DOI 10.1093/cid/ciw668